Boston Scientific Corporation

(New York Stock Exchange)
Back to all articles
Slightly Bullish +25

Do Boston Scientific's (NYSE:BSX) Earnings Warrant Your Attention?

AI-generated analysis

πŸ” Investors are warned against chasing 'story stocks' with no revenue or profit, cautioning that loss-making companies can act like a sponge for capital.

πŸ’‘ For investors preferring companies that generate revenue and profits, Boston Scientific (NYSE:BSX) is presented as a strong candidate.

πŸ“ˆ Boston Scientific has increased its earnings per share (EPS) by an average of 60% per year over the last three years.

πŸ“‰ While EPS growth is high, analysts note that such rapid growth rarely lasts long and should be monitored closely.

πŸ’° The company reported revenue growth of 17% to reach US$21 billion for the latest period.

βš–οΈ Earnings Before Interest and Tax (EBIT) margins have remained fairly unchanged over the last year.

🧠 AI is identified as a key technology set to transform healthcare, though specific Boston Scientific products in this area were not detailed.

πŸ’Ό Company insiders hold a stake worth approximately US$158 million in Boston Scientific.

πŸ‘₯ Insider ownership represents only 0.2% of the total business, which reflects the company's massive market capitalization of around US$84 billion.

πŸ“ˆ The alignment between management and shareholders is viewed positively due to insiders having significant financial 'skin in the game'.

πŸš€ Analysts suggest that fast EPS growth can indicate an inflection point in a business, creating potential investment opportunities.

πŸ“Š A free interactive visualization of Boston Scientific's forecast profits is available for further analysis.

πŸ’° While quality earnings are noted, the article advises checking if the stock trades at a high or low P/E relative to its industry.

⚠️ This specific analysis focuses on earning quality and insider confidence but has not yet calculated the intrinsic value of the stock.

πŸ“‰ A list of other US companies with promising growth potential and insider confidence is offered for further exploration.

πŸ›‘ Readers are reminded that reportable insider transactions discussed refer only to relevant jurisdiction filings.

βš–οΈ This analysis by Simply Wall St is based on historical data and unbiased methodology but does not constitute financial advice.

❌ The article explicitly states it is not a recommendation to buy or sell any stock.

🧭 Analysis may not factor in the latest price-sensitive announcements or qualitative material released after publication.

⚠️ Investors are advised that the analysis does not account for individual objectives or specific financial situations.

πŸ”’ Information regarding consumer health privacy policies and editorial contact details is provided at the end of the article.

Bullish Signals
  • Boston Scientific achieved impressive earnings per share (EPS) growth of 60% per year over the last three years.
  • The company reported strong revenue growth of 17%, reaching a total of US$21b for the period.
  • Management holds significant skin in the game with an investment valued at US$158m, demonstrating alignment with shareholder interests.
  • Despite being a large US$84b market capitalization company, insiders maintain a stake that suggests confidence in future performance.
Risk Factors
  • The article warns against chasing 'story stocks' without revenue or profit, suggesting investors should be cautious of throwing money at companies that are merely losing capital.
  • While Boston Scientific has shown strong recent growth, the text explicitly states that such high EPS growth rates rarely last long, indicating a potential future slowdown.
  • EBIT margins remained unchanged over the last year despite revenue growth, suggesting that the company is not improving its efficiency or profitability at the operating level.
  • Insiders hold a stake worth US$158m, but this represents only 0.2% of the business, which may indicate limited alignment compared to larger stakes.
  • The analysis has not yet determined if Boston Scientific is trading at a high P/E or low P/E relative to its industry, leaving valuation risk unaddressed.
  • The article notes that their analysis does not factor in the latest price-sensitive company announcements or qualitative material, creating potential information lag.
Full Analysis
Boston Scientific (NYSE:BSX) demonstrates strong financial performance with earnings per share growing 60% annually over the last three years, a metric often favored by long-term investors as it correlates with share price appreciation. Despite this high growth rate rarely lasting indefinitely, the company's consistency in generating revenue and profit is highlighted as a positive fundamental trait that distinguishes it from "story stocks" that lack profitability. Revenue grew 17% to reach US$21 billion during the reported period, while EBIT margins remained stable, indicating operational efficiency despite the scale of expansion. Insider alignment with shareholders is confirmed through significant management investment; insiders hold a stake valued at US$158 million, representing 0.2% of the total business valuation of approximately US$84 billion. Although this ownership percentage is small relative to the company's massive size, it serves as evidence that leadership is financially committed to the stock's performance and shares risk with external investors. The article suggests Boston Scientific may be approaching an inflection point where rapid earnings growth attracts further investment interest. The content concludes by recommending a closer examination of valuation metrics, specifically noting that while the quality of earnings and insider confidence are strong, investors should also check the price-to-earnings ratio relative to industry standards before adding the stock to their watchlist or portfolio. The analysis relies on historical data and forecasts rather than serving as direct financial advice, emphasizing fundamental long-term value driven by consistent profitability and insider skin-in-the-game.